NCT07041372Enrolling by invitation
Cerebral Atherosclerosis Research With Positron Emission Tomography
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are: * Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors? * Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients. Participants will: * Undergo whole-body FDG PET once their neurological status has stabilized after stroke. * Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day. * Maintain regular clinic visits for up to 24 months following the index stroke
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 310 (estimated)
- First submitted
- 19 Jun 2025
- Start date
- 22 Jun 2021
- Primary completion date
- 28 Feb 2029
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Stroke
- NCT number
- NCT07041372
What you commit to
- Study type: Observational
- Planned participants: 310
- From 22 Jun 2021 to the primary completion date, 28 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with uncontrolled diabetes requiring persistent insulin injection
- Patients with diagnosed/treatment for dementia
- Patients undergoing treatment for malignant tumors or serious autoimmune diseases
Other
- Patients with unstable vital signs or neurological symptoms
- Patients with estimated glomerular filtration rate less than 30ml/min
- During pregnancy or while breastfeeding
- Patients with impaired consent capacity
Who the study is looking for
- acute ischemic stroke patients who admitted within seven days after symptom onset
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.